OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance. We are committed to bringing forward innovative, first-in-class medicines that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.

Each product in OncoGenex’ oncology Pipeline has a distinct mechanism of action and represents a unique opportunity for cancer drug development.

Custirsen (OGX-011)
OncoGenex’ Phase 3 compound, custirsen, is designed to inhibit the production of clusterin, a protein that is associated with treatment resistance in a number of solid tumors, including prostate, breast, non-small cell lung, ovarian, and bladder cancers. Custirsen is currently being evaluated in two Phase 3 clinical trials in castrate-resistant prostate cancer, with plans to initiate a Phase 3 trial in non-small cell lung cancer in 2012.

OGX-427
Our Phase 2 product candidate, OGX-427, is designed to reduce production of heat shock protein 27 (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer tumor cell growth. Anti-cancer treatments, such as chemotherapy, hormone ablation and radiation therapy, are known to further increase levels of Hsp27. Clinical trials evaluating OGX-427 in bladder and prostate cancers are currently enrolling patients.

Preliminary OGX-427 data from Phase 1 and 2 studies in bladder and prostate cancers will be presented at the 2012 ASCO Genitourinary Cancer Symposium in February.